Increased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish men
Tóm tắt
Prospective studies have shown that low levels of circulating insulin-like growth factor binding protein-1 (IGFBP-1) are associated with the risk of type 2 diabetes. In the present study, we investigated DNA methylation in the IGFBP1 gene to evaluate its changes in relation to serum IGFBP-1 levels in type 2 diabetes. A total of 406 Swedish men, including age-matched normal glucose tolerance subjects and type 2 diabetes patients either newly diagnosed or undergoing treatment, were selected from the Stockholm Diabetes Prevention Program. IGFBP1 methylation levels in genomic DNA extracted from peripheral blood were analysed by bisulfite pyrosequencing. Serum IGFBP-1 levels were measured by radio-immunoassay. We found that IGFBP1 DNA methylation levels were higher in both newly diagnosed and treated type 2 diabetes patients with a mean diabetes duration of 3 years compared with subjects with normal glucose tolerance (19.8% and 20.2% vs. 16.9%, P < 0.001 for both). Serum levels of IGFBP-1 in newly diagnosed and in treated type 2 diabetes patients were lower compared with healthy individuals (18 μg/l both vs. 24 μg/l, P = 0.011, P < 0.001). IGFBP1 methylation levels but not serum IGFBP-1 levels in type 2 diabetes patients were independent of body mass index. Newly diagnosed patients with a family history of diabetes (FHD) had higher IGFBP1 methylation levels than those without FHD (20.3% vs. 18.6%, P = 0.017). This study provides the first evidence that changes in DNA methylation of the IGFBP1 gene are associated with type 2 diabetes in Swedish men and suggests that increased IGFBP1 DNA methylation and decreased IGFBP-1 serum levels are features of type 2 diabetes with a short duration.
Tài liệu tham khảo
Billings LK, Florez JC: The genetics of type 2 diabetes: what have we learned from GWAS?. Ann N Y Acad Sci. 2010, 1212: 59-77. 10.1111/j.1749-6632.2010.05838.x.
Ahlqvist E, Ahluwalia TS, Groop L: Genetics of type 2 diabetes. Clin Chem. 2011, 57 (2): 241-254. 10.1373/clinchem.2010.157016.
Imamura M, Maeda S: Genetics of type 2 diabetes: the GWAS era and future perspectives. Endocr J. 2011, 58 (9): 723-739. 10.1507/endocrj.EJ11-0113.
Ling C, Groop L: Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009, 58 (12): 2718-2725. 10.2337/db09-1003.
Drong AW, Lindgren CM, McCarthy MI: The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther. 2012, 92 (6): 707-715. 10.1038/clpt.2012.149.
Kirchner H, Osler ME, Krook A, Zierath JR: Epigenetic flexibility in metabolic regulation: disease cause and prevention?. Trends Cell Biol. 2013, 23 (5): 203-209. 10.1016/j.tcb.2012.11.008.
Suikkari AM, Koivisto VA, Koistinen R, Seppälä M, Yki-Järvinen H: Dose–response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab. 1989, 68 (1): 135-140. 10.1210/jcem-68-1-135.
Brismar K, Fernqvist-Forbes E, Wahren J, Hall K: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994, 79 (3): 872-878. 10.1210/jc.79.3.872.
Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM: Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Söderåkra cardiovascular risk factor study. Diabetes Metab. 2009, 35 (3): 198-205. 10.1016/j.diabet.2008.11.003.
Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE, Strickler HD: The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009, 25 (1): 3-12. 10.1002/dmrr.919.
Gokulakrishnan K, Velmurugan K, Ganesan S, Mohan V: Circulating levels of insulin-like growth factor binding protein-1 in relation to insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (Chennai urban rural epidemiology study 118). Metabolism. 2012, 61 (1): 43-46. 10.1016/j.metabol.2011.05.014.
Hong Y, Brismar K, Hall K, Pedersen NL, de Faire U: Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J Endocrinol. 1997, 153 (2): 251-257. 10.1677/joe.0.1530251.
Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K: Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia. 2008, 51 (7): 1135-1145. 10.1007/s00125-008-1016-x.
Lewitt MS, Hilding A, Brismar K, Efendic S, Ostenson CG, Hall K: IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur J Endocrinol. 2010, 163 (2): 233-242. 10.1530/EJE-10-0301.
Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009, 462 (7271): 315-322. 10.1038/nature08514.
Murrell A, Rakyan VK, Beck S: From genome to epigenome. Hum Mol Genet. 2005, S1: R3-R10.
Schumacher A, Petronis A: Epigenetics of complex diseases: from general theory to laboratory experiments. Curr Top Microbiol Immunol. 2006, 310: 81-115. 10.1007/3-540-31181-5_6.
Barrès R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A, O’Gorman DJ, Zierath JR: Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab. 2012, 15 (3): 405-411. 10.1016/j.cmet.2012.01.001.
Yin H, Blanchard KL: DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms. Blood. 2000, 95 (1): 111-119.
Rehman JU, Brismar K, Holmbäck U, Akerstedt T, Axelsson J: Sleeping during the day: effects on the 24-h patterns of IGF-binding protein 1, insulin, glucose, cortisol, and growth hormone. Eur J Endocrinol. 2010, 163 (3): 383-390. 10.1530/EJE-10-0297.
Humphriss DB, Stewart MW, Berrish TS, Barriocanal LA, Trajano LR, Ashworth LA, Brown MD, Miller M, Avery PJ, Alberti KG, Walker M: Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia. 1997, 40 (10): 1185-1190. 10.1007/s001250050805.
Eriksson AK, Ekbom A, Granath F, Hilding A, Efendic S, Ostenson CG: Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med. 2008, 25 (7): 834-842. 10.1111/j.1464-5491.2008.02463.x.
Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15 (7): 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
Tost J, Dunker J, Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. BioTechniques. 2003, 35 (1): 152-156.
Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. BioTechniques. 2003, 35 (1): 146-150.
Póvoa G, Roovete A, Hall K: Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh). 1984, 107 (4): 563-570.
Grill V, Pigon J, Hartling SG, Binder C, Efendic S: Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism. 1990, 39 (3): 251-258. 10.1016/0026-0495(90)90043-C.
Bang P, Eriksson U, Sara V, Wivall IL, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh). 1991, 124 (6): 620-629.